| pubmed-article:15851628 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15851628 | lifeskim:mentions | umls-concept:C0011854 | lld:lifeskim |
| pubmed-article:15851628 | lifeskim:mentions | umls-concept:C0162574 | lld:lifeskim |
| pubmed-article:15851628 | lifeskim:mentions | umls-concept:C0009566 | lld:lifeskim |
| pubmed-article:15851628 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:15851628 | lifeskim:mentions | umls-concept:C0949236 | lld:lifeskim |
| pubmed-article:15851628 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:15851628 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:15851628 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15851628 | pubmed:dateCreated | 2005-6-24 | lld:pubmed |
| pubmed-article:15851628 | pubmed:abstractText | We investigated the associations of pulse pressure (a measure of arterial stiffness) with the early glycation products hemoglobin A1c (HbA1c) and Amadori albumin and the advanced glycation end products pentosidine, Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in a large group of type 1 diabetic individuals of the EURODIAB Prospective Complications Study. We did a cross-sectional nested case-control study from the EURODIAB Prospective Complications Study of 543 (278 men) European individuals with type 1 diabetes diagnosed at <36 years of age. We used linear regression analyses to investigate the association of pulse pressure with glycation products. Pulse pressure was significantly associated with plasma levels of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine but not with HbA1c, Amadori albumin, and urinary levels of pentosidine. Regression coefficients adjusted for age, sex, mean arterial pressure, and duration of diabetes were 0.09 mm Hg (P=0.003) per 1 microM/M lysine Nepsilon-(carboxymethyl)lysine; 0.24 mm Hg (P=0.001) and -0.03 mm Hg (P=0.62) per 1 microM/M lysine Nepsilon-(carboxyethyl)lysine (in individuals with and without complications, respectively; P interaction=0.002); and 0.50 mm Hg (P=0.16) per 1% HbA1c; 0.07 mm Hg (P=0.12) per 1 U/mL Amadori albumin; and 0.77 mm Hg (P=0.48) per 1 nmol/mmol creatinine pentosidine. In young type 1 diabetic individuals, arterial stiffness is strongly associated with the advanced glycation end products Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine. These findings suggest that the formation of advanced glycation end products is an important pathway in the development of arterial stiffness in young type 1 diabetic individuals. | lld:pubmed |
| pubmed-article:15851628 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15851628 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15851628 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15851628 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15851628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15851628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15851628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15851628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15851628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15851628 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15851628 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:15851628 | pubmed:issn | 1524-4563 | lld:pubmed |
| pubmed-article:15851628 | pubmed:author | pubmed-author:ChaturvediNis... | lld:pubmed |
| pubmed-article:15851628 | pubmed:author | pubmed-author:FullerJohn... | lld:pubmed |
| pubmed-article:15851628 | pubmed:author | pubmed-author:EURODIAB... | lld:pubmed |
| pubmed-article:15851628 | pubmed:author | pubmed-author:SchalkwijkCas... | lld:pubmed |
| pubmed-article:15851628 | pubmed:author | pubmed-author:StehouwerCoen... | lld:pubmed |
| pubmed-article:15851628 | pubmed:author | pubmed-author:SchramMiranda... | lld:pubmed |
| pubmed-article:15851628 | pubmed:author | pubmed-author:BootsmaAart... | lld:pubmed |
| pubmed-article:15851628 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:15851628 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:15851628 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15851628 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15851628 | pubmed:pagination | 232-7 | lld:pubmed |
| pubmed-article:15851628 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:meshHeading | pubmed-meshheading:15851628... | lld:pubmed |
| pubmed-article:15851628 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15851628 | pubmed:articleTitle | Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. | lld:pubmed |
| pubmed-article:15851628 | pubmed:affiliation | Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. | lld:pubmed |
| pubmed-article:15851628 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15851628 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15851628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15851628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15851628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15851628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15851628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15851628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15851628 | lld:pubmed |
